Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$2.25
-1.7%
$2.09
$0.98
$3.44
$89.91M0.1732,173 shs15,121 shs
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
$9.07
$0.82
$3.60
$162.00M1.17547,540 shsN/A
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
$4.10
$4.10
$1.89
$6.37
$355.05M1.891.16 million shs34.93 million shs
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
$1.10
$1.08
$0.59
$8.08
$36.47M0.1701,788 shsN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$18.44
$18.12
$5.80
$20.96
$1.94B2.081.87 million shs8 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
0.00%-8.16%+33.53%+67.91%-8.91%
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
0.00%0.00%0.00%0.00%+97.27%
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/AN/AN/AN/A
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
N/AN/AN/AN/AN/AN/AN/AN/A
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
0.00
N/AN/AN/A
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
0.00
N/AN/AN/A
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
0.00
N/AN/AN/A
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
0.00
N/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/A($0.37) per shareN/A
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
$940K0.00N/AN/A$2.11 per share0.00
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
$34.99M10.15N/AN/A$0.54 per share7.59
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/A$1.41 per shareN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$150K12,907.39N/AN/A$2.56 per share7.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$11.12MN/A0.00N/AN/AN/AN/AN/A
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
-$42.99M-$1.03N/AN/AN/A-4,592.84%-41.50%-33.95%N/A
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
-$68.55M-$0.80N/AN/AN/A-180.28%-129.46%-53.23%N/A
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
-$70.06M-$2.01N/AN/AN/AN/A-115.24%-102.26%N/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/A

Latest PGNX, NLNK, BYSI, TRIL, and STSA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A-$0.06N/A$0.11N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/A
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
N/AN/AN/AN/AN/A
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
N/AN/AN/AN/AN/A
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A
2.49
2.49
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
N/A
7.98
7.98
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
0.99
2.12
2.12
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/A
7.44
7.44
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/A
19.82
19.82
CompanyEmployeesShares OutstandingFree FloatOptionable
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
8040.32 million28.50 millionOptionable
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
5537.33 millionN/ANot Optionable
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
7986.60 millionN/AOptionable
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
2133.15 million22.81 millionNot Optionable
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
33105.00 million95.44 millionOptionable

Recent News About These Companies

Trillium Therapeutics Stock Price History
TTI Consumer Power Tools, Inc. is Seeking an IP Paralegal
Advances in Drug Discovery & Development 2024
Cachet Bicycle shakes off COVID
BridgeBio raises $1.25bn, and other biotech financings
Ratio Therapeutics Raises $50M in Series B Financing
Leukemia Therapeutics Global Market Report 2023

Media Sentiment Over Time

Top Headlines

View All Headlines
BeyondSpring stock logo

BeyondSpring NASDAQ:BYSI

$2.25 -0.04 (-1.75%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

NewLink Genetics stock logo

NewLink Genetics NASDAQ:NLNK

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

Progenics Pharmaceuticals stock logo

Progenics Pharmaceuticals NASDAQ:PGNX

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

Satsuma Pharmaceuticals stock logo

Satsuma Pharmaceuticals NASDAQ:STSA

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Trillium Therapeutics stock logo

Trillium Therapeutics NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.